Regarding acute promyelocytic leukemia (APL/AML-M3), all of the following statements are correct EXCEPT:

Question

Accepted Answer

D. The abnormal promyelocytes contain abundant Auer rods and are resistant to standard chemotherapy alone. ## Acute Promyelocytic Leukemia (APL): Molecular and Clinical Features

**Key Point:** While APL promyelocytes DO contain abundant Auer rods ("bundles of sticks"), they are NOT inherently resistant to standard chemotherapy. In fact, APL is highly chemosensitive and has one of the best prognoses among acute leukemias, especially with modern ATRA/ATO-based therapy.

### t(15;17) Translocation and PML-RARA Fusion

```mermaid
flowchart TD
  A[t15;17 translocation]:::outcome --> B[PML-RARA fusion gene]:::outcome
  B --> C[Abnormal retinoic acid receptor]:::outcome
  C --> D[Blocks myeloid differentiation]:::outcome
  D --> E[Accumulation of abnormal promyelocytes]:::outcome
```

**High-Yield:** The PML-RARA fusion protein acts as a dominant-negative inhibitor of wild-type RARA, preventing normal myeloid differentiation and causing the characteristic morphology.

### ATRA and Arsenic Trioxide: Paradigm Shift

| Aspect | Details |
|--------|----------|
| **ATRA mechanism** | Binds RARA, overcomes differentiation block, induces maturation |
| **ATO mechanism** | Induces apoptosis of leukemic cells; also degrades PML-RARA protein |
| **Cure rates** | >90% with ATRA + ATO combination (vs. ~70% with chemotherapy alone) |
| **Early mortality** | DIC management is critical during initial phase |
| **Differentiation syndrome** | Can occur with ATRA; managed with corticosteroids |

**Clinical Pearl:** APL is now considered a medical oncology success story—one of the first cancers where targeted molecular therapy (ATRA) dramatically improved outcomes without relying solely on cytotoxic chemotherapy.

### DIC in APL: A Hallmark Feature

1. **Mechanism:** Abnormal promyelocytes release procoagulant substances (tissue factor, cancer procoagulant)
2. **Timing:** Present at diagnosis in ~80% of cases; worsens during initial ATRA treatment
3. **Management:** Fresh frozen plasma, platelet transfusions, heparin (controversial), ATRA + ATO
4. **Mortality:** DIC-related bleeding is the leading cause of early death if not managed aggressively

### Auer Rods in APL

**Mnemonic:** **Bundles of sticks** = characteristic appearance of multiple Auer rods in APL promyelocytes.

- Abundant and distinctive in APL
- Highly specific but NOT required for diagnosis
- Do NOT confer chemotherapy resistance
- Present in ~80% of APL cases

**Why the Distractor is Wrong:** The statement conflates two unrelated facts—APL promyelocytes DO have abundant Auer rods, but this morphology does NOT indicate chemotherapy resistance. APL is actually highly chemosensitive and responds excellently to ATRA/ATO.

Answer

A. t(15;17) translocation results in fusion of PML and RARA genes, creating an abnormal retinoic acid receptor

Answer

B. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are now standard frontline treatments with cure rates >90%

Answer

C. Disseminated intravascular coagulation (DIC) is a common presenting feature and major cause of early mortality

Regarding acute promyelocytic leukemia (APL/AML-M3), all of the following statements are correct EXCEPT:

Explanation

Acute Promyelocytic Leukemia (APL): Molecular and Clinical Features

t(15;17) Translocation and PML-RARA Fusion

ATRA and Arsenic Trioxide: Paradigm Shift

DIC in APL: A Hallmark Feature

Auer Rods in APL

Practice similar questions

Join our NEET PG community

Aspect	Details
ATRA mechanism	Binds RARA, overcomes differentiation block, induces maturation
ATO mechanism	Induces apoptosis of leukemic cells; also degrades PML-RARA protein
Cure rates	>90% with ATRA + ATO combination (vs. ~70% with chemotherapy alone)
Early mortality	DIC management is critical during initial phase
Differentiation syndrome	Can occur with ATRA; managed with corticosteroids